AmCad BioMed Corporation
AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company's products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-US, … Read more
AmCad BioMed Corporation (4188) - Net Assets
Latest net assets as of December 2025: $U600.82 Million UYU
Based on the latest financial reports, AmCad BioMed Corporation (4188) has net assets worth $U600.82 Million UYU as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($U622.70 Million) and total liabilities ($U21.88 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $U600.82 Million |
| % of Total Assets | 96.49% |
| Annual Growth Rate | 0.93% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 20.85 |
AmCad BioMed Corporation - Net Assets Trend (2021–2025)
This chart illustrates how AmCad BioMed Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AmCad BioMed Corporation (2021–2025)
The table below shows the annual net assets of AmCad BioMed Corporation from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $U600.82 Million | -9.48% |
| 2024-12-31 | $U663.72 Million | +38.87% |
| 2023-12-31 | $U477.95 Million | -8.05% |
| 2022-12-31 | $U519.78 Million | -10.23% |
| 2021-12-31 | $U579.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to AmCad BioMed Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11451500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $U774.51 Million | 148.54% |
| Total Equity | $U521.42 Million | 100.00% |
AmCad BioMed Corporation Competitors by Market Cap
The table below lists competitors of AmCad BioMed Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Airtime Partecipazioni SpA
PA:ALMEX
|
$9.71 Million |
|
Robit Oyj
HE:ROBIT
|
$9.71 Million |
|
Huron Valley Bancorp Inc
PINK:HVLM
|
$9.72 Million |
|
Samil Co.Ltd
KQ:032280
|
$9.72 Million |
|
Hawsons Iron Ltd
AU:HIO
|
$9.71 Million |
|
PT MNC Energy Investments Tbk
JK:IATA
|
$9.71 Million |
|
Delta Israel Brands Ltd
TA:DLTI
|
$9.71 Million |
|
Pacgold Ltd
AU:PGO
|
$9.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AmCad BioMed Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 568,652,000 to 521,424,000, a change of -47,228,000 (-8.3%).
- Net loss of 55,719,000 reduced equity.
- Other factors increased equity by 8,491,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $U-55.72 Million | -10.69% |
| Other Changes | $U8.49 Million | +1.63% |
| Total Change | $U- | -8.31% |
Book Value vs Market Value Analysis
This analysis compares AmCad BioMed Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.58x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.43x to 1.58x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $U9.07 | $U13.00 | x |
| 2022-12-31 | $U7.98 | $U13.00 | x |
| 2023-12-31 | $U7.15 | $U13.00 | x |
| 2024-12-31 | $U8.98 | $U13.00 | x |
| 2025-12-31 | $U8.23 | $U13.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AmCad BioMed Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -183.06%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.19x
- Recent ROE (-10.69%) is below the historical average (-9.87%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -5.29% | -29.77% | 0.14x | 1.27x | $U-73.84 Million |
| 2022 | -12.60% | -86.79% | 0.11x | 1.30x | $U-95.95 Million |
| 2023 | -11.91% | -69.44% | 0.13x | 1.35x | $U-83.37 Million |
| 2024 | -8.89% | -95.24% | 0.08x | 1.22x | $U-107.44 Million |
| 2025 | -10.69% | -183.06% | 0.05x | 1.19x | $U-107.86 Million |
Industry Comparison
This section compares AmCad BioMed Corporation's net assets metrics with peer companies in the Medical Devices industry.
No peer company data available for comparison.